{"id":8172,"date":"2026-10-23T18:25:03","date_gmt":"2026-10-23T12:55:03","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-23\/"},"modified":"2026-10-23T23:48:03","modified_gmt":"2026-10-23T18:18:03","slug":"torntpharm-share-price-today-2026-10-23","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-23\/","title":{"rendered":"Torrent Pharmaceuticals L Share Price Today: Why TORNTPHARM Is Falling 1.97% | 23 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: TORNTPHARM<\/strong> \u00b7 23 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b94,524.40<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-1.97%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b94,650.70 \/ \u20b94,476.10<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b94,615.30<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>3.29 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>23 October 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Torrent Pharmaceuticals Limited shares fell 1.97% to close at \u20b94,524.40 on October 23, 2026, after opening higher at \u20b94,630.50.<\/li>\n<li>Torrent Pharmaceuticals submitted its standalone and consolidated financial results for the quarter and half year ended September 30, 2026, following board approval. Standalone revenue from operations was reported at \u20b94,145 crores with a net profit of \u20b9498 crores for the quarter. The statutory auditors issued an unmodified audit report on the standalone financial results.<\/li>\n<li>Trading volume was 1.04 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Torrent Pharmaceuticals L share price falling on 23 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Torrent Pharmaceuticals Limited shares fell 1.97% to close at \u20b94,524.40 on October 23, 2026, after opening higher at \u20b94,630.50.<\/p>\n<p class=\"wt-copy\">The broader market and pharmaceutical sector experienced downward pressure during the session, with the Nifty falling 0.39% and the Nifty Pharma sector benchmark declining 1.04%. Torrent Pharmaceuticals underperformed both the headline index and its sector gauge. Over a broader timeframe, the stock has declined 1.30% over the last 5 trading days and 9.24% over the past 20 trading days, placing today&#x27;s move in the context of recent downward momentum.<\/p>\n<p class=\"wt-copy\">Company disclosures showed that Torrent Pharmaceuticals released its financial results for the quarter and half year ended September 30, 2026, following a board meeting on October 23, 2026. The financial statements report quarterly revenue from operations at \u20b94,145 crores and net profit at \u20b9498 crores. While the earnings update provides important fundamental context regarding the company&#x27;s operating performance, no single confirmed trigger links the release directly to today&#x27;s 1.97% price decrease.<\/p>\n<p class=\"wt-copy\">3.29 lakh shares traded by 23 October 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 3.16 lakh shares (1.04 times). The five-day average daily volume was 2.23 lakh shares. Separately, the NSE report for 23 October 2026 showed 1.88 lakh shares delivered, representing 57.10% of that day\u2019s traded volume. The same report recorded 31,905 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Sector weakness and profit-taking following recent earnings announcements<\/strong><\/p>\n<p class=\"wt-copy\">The stock declined alongside broader weakness in the Nifty Pharma sector and the broader market, extending recent 20-day downward momentum despite the release of quarterly financial results.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">September 2026 Quarter Financial Results<\/div>\n<div class=\"wt-card-date\">23 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Torrent Pharmaceuticals submitted its standalone and consolidated financial results for the quarter and half year ended September 30, 2026, following board approval. Standalone revenue from operations was reported at \u20b94,145 crores with a net profit of \u20b9498 crores for the quarter. The statutory auditors issued an unmodified audit report on the standalone financial results.<\/p>\n<p class=\"wt-copy\">Quarterly earnings figures provide essential visibility into the company&#x27;s revenue growth, operational margins, and overall financial health.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Resignation of Executive Director Amal Kelshikar<\/div>\n<div class=\"wt-card-date\">16 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced that Amal Kelshikar, Executive Director designated as a Senior Management Personnel, tendered his resignation effective from the close of business hours on October 16, 2026. In his resignation letter, Kelshikar noted he was stepping down after thoughtful reflection following an extended tenure beyond superannuation.<\/p>\n<p class=\"wt-copy\">Changes in senior management personnel are key governance updates that affect executive oversight and leadership continuity.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_16102026180229_SE_IntimationSMP.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Credit Rating Affirmation and Outlook Revision<\/div>\n<div class=\"wt-card-date\">7 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">India Ratings and Research Private Limited affirmed Torrent Pharmaceuticals&#x27; existing banking facilities, issuer rating, and Non-Convertible Debentures while revising the outlook from stable to positive at IND AA+\/Positive. Additionally, the rating agency affirmed and assigned credit ratings for existing and proposed commercial paper at IND A1+.<\/p>\n<p class=\"wt-copy\">An upgraded rating outlook reflects independent validation of the company&#x27;s credit strength and financial stability.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">23 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 23, 2026, titled &quot;A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an Annexure B.&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_23102026165000_outcome.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">23 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_23102026164512_Results.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">60.78%<\/div>\n<div class=\"wt-note\">60.78% on 20 July 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">17.22%<\/div>\n<div class=\"wt-note\">17.97% on 20 July 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">30.68%<\/div>\n<div class=\"wt-note\">30.84% on 20 July 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739383_15102026075118_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Jinesh Shah, Designated Person (in capacity of trustee of Jinesh Trust)<\/strong><span class=\"wt-note\">Other<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>9.30 lakh shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>27 November 2024<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 8.82% on 30 September 2026. This compares with 8.27% on 20 July 2026, a change of +0.55 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 46 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">43.41 lakh shares \u00b7 1.14%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">AXIS MUTUAL FUND TRUSTEE LIMITED A\/C AXIS MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">42.44 lakh shares \u00b7 1.12%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">KOTAK DEBT HYBRID<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">39.96 lakh shares \u00b7 1.05%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739383_15102026075118_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Post-earnings analyst conference call outcomes and management commentary on demand trends<\/li>\n<li>Execution of domestic and international branded formulation strategies<\/li>\n<li>Volume and delivery trends around the \u20b94,500 price level<\/li>\n<li>Subsequent credit rating and debt profile updates<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-08\/\">Torrent Pharmaceuticals in Focus After Credit Rating Outlook Upgrade | 8 October 2026 \u2014 8 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-01\/\">Why Torrent Pharma Shares Fell 2.82% Today: Sector Weakness | 1 October 2026 \u2014 1 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-09-29\/\">Why Torrent Pharma Share Price is Down Today | TORNTPHARM Analysis | 29 September 2026 \u2014 29 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/torntpharm\/\">More Torrent Pharmaceuticals L news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Torrent Pharmaceuticals L company news?<\/h3>\n<p class=\"wt-copy\">Torrent Pharmaceuticals submitted its standalone and consolidated financial results for the quarter and half year ended September 30, 2026, following board approval. Standalone revenue from operations was reported at \u20b94,145 crores with a net profit of \u20b9498 crores for the quarter. The statutory auditors issued an unmodified audit report on the standalone financial results.<\/p>\n<h3>How strong was Torrent Pharmaceuticals L\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">3.29 lakh shares traded, 1.04 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-23\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/torntpharm-share-price-today-2026-10-23\/\"}, \"headline\": \"Torrent Pharmaceuticals L Share Price Today: Why TORNTPHARM Is Falling 1.97% | 23 October 2026\", \"description\": \"Torrent Pharmaceuticals L share price fell 1.97% to \u20b94,524.40 today. See why TORNTPHARM is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-23T12:55:03Z\", \"dateModified\": \"2026-10-23T23:47:56.108388+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/torntpharm-company-news-2026-10-23.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 23, 2026, titled \\\"A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an Annexure B.\\\".\",\"source\":\"NSE\",\"published\":\"23-Oct-2026 16:50:10\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_23102026165000_outcome.pdf\",\"disclosure_text\":\"Email \u2013 investorservices@torrentpharma.com 23rd October, 2026 The Dy. General Manager (Listing Dept.) The Manager \u2013 Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5 th Floor, 1st Floor, New Trading Ring, Plot No. C\/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai \u2013 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Submission \/ Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cListing Regulations\u201d) We would like to inform that the Board has at its meeting held today approved, inter alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with limited review report of the Company for the quarter and half year ended 30th September, 2026. The said financial results are enclosed herewith as an Annexure A. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and half year ended on 30 th September, 2026. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as an Annexure B. The Board meeting commenced at 02:00 pm and concluded at 04:00 pm. The above is for your information and record. Thanking you, Yours Sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Encl: A\/a TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com Annexure A BS R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai -400 063, India Telephone +91 (22) 6257 1000 . Fax +91 (22) 6257 1010 lndeoendent Auditor's Reoort To the Board of Directors of Torrent Pharmaceuticals Limited Report on the audit of the Standalone Financial Results Opinion We have audited the accompanying standalone quarterly financial results of Torrent Pharmaceuticals Limited (\\\"the Company\\\") for the quarter ended 30 September 2026 and the year-to-date results for the period from 1 April 2026 to 30 September 2026 (in which are included the standalone financial information of erstwhile J. B. Chemicals & Pharmaceuticals Limited (JBCPL), pursuant to the Scheme of Arrangement in the nature of Amalgamation of JBCPL with the Company which has been approved by the National Company Law Tribunal vide its order dated 06 July 2026 with the appointed date of 21 January 2026), attact1ed herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (\\\"Listing Regulations\\\"), as prescribed in Securities and Exchange Board of India operational circular SEBI\/HO\/DDHS\/P\/CIR\/2021\/613 dated 10 August 2021. In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results: a. are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI\/HO\/DDHS\/P\/CIR\/2021\/613 dated 10 August 2021 in this regard; and b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the quarter ended 30 September 2026 as well as for the year to date results for the period from 1 April 2026 to 30 September 2026. Basis for Opinion We conducted our audit in accordance with the Standards on Auditing (\\\"SAs\\\") specified under section 143(10) of the Companies Act, 2013 (\\\"the Act\\\"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion. Management's and Board of Directors' Responsibilities for the Standalone Financial Results These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Management and the Board of Directors are responsible for the preparation of these standalone financial results that give a true and fair view of the net profit\/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted <? -!;>\\u002d\\u002d BS R & Co. (a partnership firm with Registration No. BA61223) converted into BS R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-6181) with effect from October 14, 2013 Registered Office: 14th F(oor, Central B Wng and North C Wing, Nesco IT Pa~ 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai -400063 Page 1 of 3 8 SR & Co. LLP Independent Auditor's Report (Continued) Torrent Pharmaceuticals Limited in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI\/HO\/DDHS\/P\/CIR\/2021\/613 dated 10 August 2021. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the standalone financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern , disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is also responsible for overseeing the Company's financial reporting process. Auditor's Responsibilities for the Audit of the Standalone Financial Results Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance , but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also: Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors. Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained , whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion . Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures , and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation . We communicate with those charged with governance regarding, among other matters, the planned scope and ti min of the audit and significant audit findings , including any significant deficiencies in internal control th ......:::=-=::::-,... our audit. Page 2 of 3 BS R & Co. LLP Independent Auditor's Report (Continued) Torrent Pharmaceuticals Limited We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. Other Matter The corresponding amounts for the year ended 31 March 2026, includes financial results of JBCPL (considered pursuant to the Scheme of Amalgamation of JBCPL with the Company as stated in Note 5), whose financial results reflect total assets of Rs. 4,823.50 crores as at 31 March 2026, total revenue of Rs. 712.74 crores, total net profit after tax of Rs. 133.97 crores and total comprehensive income of Rs. 136.45 crores, for the period from 21 January 2026 to 31 March 2026. These financial results of JBCPL has been audited by other auditor who had expressed an unmodified opinion. Our opinion is not modified in respect of this matter. Ahmedabad 23 October 2026 For B S R & Co. LLP Chartered Accountants Firm's Registration No.: 101248W\/W-100022 Sadashiv Shetty Partner Membership No.: 048648 UDIN:26048648EXELKZ5012 Page 3 of 3 TORRENT\\\" PHARMA TORRENT PHARMACEUTICALS LIMITED Registered Office: \\\"Avirat'', Thaltej Shilaj Road, Ahmedabad - 380059, Gujarat, India, Ph.:+ 91 79 26599000 Fax:+ 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com Statement of Standalone Financial Results for the Quarter and Half Year ended September 30, 2026 Quarter ended Half Year ended 30-Sep-2026 30-Jun-2026 30-Sep-2025 30-Sep-2026 30-Sep-2025 Particulars Audited Unaudited Audited Audited Audited 1 Revenue from operations (a) Revenue from contracts with customers 4063 4073 2707 8136 5274 (b) Other operating income 82 85 55 167 104 Total revenue from operations 4145 4158 2762 8303 5378 2 Other income (Refer Note 8) (11) (21) (27) (32) (32) 3 Total income (1 + 2) 4134 4137 2735 8271 5346 4 Expenses (a) Cost of materials consumed 584 609 382 1193 776 (b) Purchases of stock-in-trade 369 277 186 646 359 (c) Changes in inventories of finished goods, work-in-progress 5 52 53 57 70 and stock-in-trade (d) Employee benefits expense 669 677 460 1346 913 (e) Finance costs 287 293 37 580 82 (f) Depreciation and amortisation expense 587 575 189 1162 376 (g) Other expenses 947 970 609 1917 1209 Total expenses 3448 3453 1916 6901 3785 5 Profit before exceptional items and tax (3 - 4) 686 684 819 1370 1561 6 Exceptional items (Refer Note 6) 10 21 13 31 13 7 Profit before tax (5 - 6) 676 663 806 1339 1548 8 Tax expense (a) Current tax 260 266 220 526 418 (b) Deferred tax (82) (95) (11) (177) (18) Total tax expense 178 171 209 349 400 9 Net profit for the period (7 \u2022 8) 498 492 597 990 1148 10 Other comprehensive income (A) (i) Items that will not be reclassified subsequently to (12) (17) (2) (29) (11) profit or loss (ii) Income tax relating to items that will not be 3 4 1 7 3 reclassified subsequently to profit or loss (B) (i) Items that will be reclassified subsequently to profit 18 107 (72) 125 (99) or loss (ii) Income tax relating to items that will be reclassified (4) {27) 18 {31) 25 subsequently to profit or loss Total other comprehensive income 5 67 (55) 72 (82) 11 Total comprehensive income (9 + 10) 503 559 542 1062 1066 12 Paid-up equity share capital (Face value of Rs. 5 each) 190.18 169.23 169.23 190.18 169.23 13 Other equity excluding revaluation reserves 14 Earnings per share (Face value of Rs. 5 each) (not annualised): Basic (in Rs.) 13.09 12.94 17.64 26.03 33.92 Diluted (in Rs.) 13.09 12.94 17.64 26.03 33.92 See accompanying notes to the standalone financial results ( Rs. in crores) Year ended 31-Mar-2026 Audited, Restated (Refer note 5) 11199 223 11422 (70) 11352 1748 832 (47) 1990 342 1057 2620 8542 2810 89 2721 767 (80) 687 2034 (3) 1 (191) 48 (145) 1889 169.23 17407 58.70 58.70 TORRENT\\\" PHARMA Notes: 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on October 23, 2026. The statutory auditors have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results. 2 The Company operates in a single segment i.e. Generic Formulation Business. 3 Standalone Balance Sheet Particulars A ASSETS 1 Non-current assets Property, plant and equipment Capital work-in-progress Investment properties Right-of-use assets Goodwill Other intangible assets Intangible assets under development Financial assets Investments Loans Other financial assets Other tax assets (net) Other non-current assets Total non-current assets 2 Current assets Inventories Financial assets Investments Trade receivables Cash and cash equivalents Bank balances other than cash and cash equivalents Loans Other financial assets Other current assets Total current assets 3 Non-current assets held for sale TOTAL ASSETS (1+2+3) (Rs. in crores) Audited As at 30-Sep-2026 As at 31-Mar-2026 Restated (Refer note S) 4123 3961 400 445 13 13 553 562 3917 3917 23234 24165 22 36 887 855 2 3 20 33 909 891 58 86 28 31 33257 34107 2221 2170 2073 866 3606 3350 82 97 22 48 5 5 220 531 6008 4897 574 538 8803 7605 1 1 42061 41713 TORRENT'\\\" PHARMA (Rs. in crores) Audited Particulars As .at As at 30-Sep-2026 31-Mar-2026 Restated (Refer note 5) B EQUITY AND LIABILITIES 1 Equity Equity share capital 190 169 Other equity 18066 17407 Total equity 18256 17576 2 Non-current liabilities Financial liabilities Borrowings 11428 11462 Lease liabilities 92 94 Other financial liabilities 29 86 11549 11642 Provisions 700 579 Deferred tax liabilities (net) 5524 5677 Other non-current liabilities 1 4 Total non-current liabilities 17774 17902 3 Current liabilities Financial liabilities Borrowings 1707 2703 Lease liabilities 22 21 Trade payables Total outstanding dues of micro enterprises and small enterprises 130 163 Total outstanding dues of creditors other than micro enterprises and 1131 1011 small enterprises Other financial liabilities 2147 1890 5137 5788 Other current liabilities 95 97 Provisions 298 280 Current tax liabilities (net) 501 70 Total current liabilities 6031 6235 TOTAL EQUITY AND LIABILITIES (1+2+3j 42061 41713 TORRENT'\\\" PHARMA 4 Standalone Statement of Cash Flows {Rs. in crores) Audited Particulars Half Vear ended Half Vear ended 30-Sep-2026 30-Sep-2025 A CASH FLOWS FROM OPERATING ACTIVITIES PROFIT BEFORE TAX 1339 1548 Adjustments for : Depreciation and amortisation expense 1162 376 Allowance for expected credit loss (net)* 6 0 Unrealised foreign exchange loss (net) 29 40 Loss on disposal of property, plant & equipment and other intangible assets 4 1 (including non-current assets held for sale) (net) Gain on sale of current investments (net) (53) (9) Finance costs 580 82 Rent income (2) - Interest income (9) (2) 3056 2036 Movement in working capital : Trade receivables (346) (428) Loans and other assets (10) (126) Inventories (51) 68 Trade payables 87 (7) Liabilities and provisions 63 (91) CASH GENERATED FROM OP\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"23-Oct-2026 16:45:57\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_23102026164512_Results.pdf\",\"disclosure_text\":\"Email \u2013 investorservices@torrentpharma.com 23rd October, 2026 The Dy. General Manager (Listing Dept.) The Manager \u2013 Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5 th Floor, 1st Floor, New Trading Ring, Plot No. C\/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai \u2013 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Submission \/ Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cListing Regulations\u201d) We would like to inform that the Board has at its meeting held today approved, inter alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with limited review report of the Company for the quarter and half year ended 30th September, 2026. The said financial results are enclosed herewith as an Annexure A. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and half year ended on 30 th September, 2026. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as an Annexure B. The Board meeting commenced at 02:00 pm and concluded at 04:00 pm. The above is for your information and record. Thanking you, Yours Sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Encl: A\/a TORRENI PHARMA TORRENT PHARMACEUTICALS LIMITED CIN, L24230GJ1972PLC002126 Regd. Office, Avirat, Thaltej Shilaj Road, Ahmedabad - 380059 Phone, +91 79 26599000, Fax, +91 79 26582100, www.torrentpharma.com Annexure A BS R & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Goregaon (East), Mumbai -400 063, India Telephone +91 (22) 6257 1000 . Fax +91 (22) 6257 1010 lndeoendent Auditor's Reoort To the Board of Directors of Torrent Pharmaceuticals Limited Report on the audit of the Standalone Financial Results Opinion We have audited the accompanying standalone quarterly financial results of Torrent Pharmaceuticals Limited (\\\"the Company\\\") for the quarter ended 30 September 2026 and the year-to-date results for the period from 1 April 2026 to 30 September 2026 (in which are included the standalone financial information of erstwhile J. B. Chemicals & Pharmaceuticals Limited (JBCPL), pursuant to the Scheme of Arrangement in the nature of Amalgamation of JBCPL with the Company which has been approved by the National Company Law Tribunal vide its order dated 06 July 2026 with the appointed date of 21 January 2026), attact1ed herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (\\\"Listing Regulations\\\"), as prescribed in Securities and Exchange Board of India operational circular SEBI\/HO\/DDHS\/P\/CIR\/2021\/613 dated 10 August 2021. In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results: a. are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI\/HO\/DDHS\/P\/CIR\/2021\/613 dated 10 August 2021 in this regard; and b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the quarter ended 30 September 2026 as well as for the year to date results for the period from 1 April 2026 to 30 September 2026. Basis for Opinion We conducted our audit in accordance with the Standards on Auditing (\\\"SAs\\\") specified under section 143(10) of the Companies Act, 2013 (\\\"the Act\\\"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion. Management's and Board of Directors' Responsibilities for the Standalone Financial Results These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Management and the Board of Directors are responsible for the preparation of these standalone financial results that give a true and fair view of the net profit\/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted <? -!;>\\u002d\\u002d BS R & Co. (a partnership firm with Registration No. BA61223) converted into BS R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-6181) with effect from October 14, 2013 Registered Office: 14th F(oor, Central B Wng and North C Wing, Nesco IT Pa~ 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai -400063 Page 1 of 3 8 SR & Co. LLP Independent Auditor's Report (Continued) Torrent Pharmaceuticals Limited in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI\/HO\/DDHS\/P\/CIR\/2021\/613 dated 10 August 2021. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the standalone financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern , disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is also responsible for overseeing the Company's financial reporting process. Auditor's Responsibilities for the Audit of the Standalone Financial Results Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance , but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also: Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors. Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained , whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion . Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures , and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation . We communicate with those charged with governance regarding, among other matters, the planned scope and ti min of the audit and significant audit findings , including any significant deficiencies in internal control th ......:::=-=::::-,... our audit. Page 2 of 3 BS R & Co. LLP Independent Auditor's Report (Continued) Torrent Pharmaceuticals Limited We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. Other Matter The corresponding amounts for the year ended 31 March 2026, includes financial results of JBCPL (considered pursuant to the Scheme of Amalgamation of JBCPL with the Company as stated in Note 5), whose financial results reflect total assets of Rs. 4,823.50 crores as at 31 March 2026, total revenue of Rs. 712.74 crores, total net profit after tax of Rs. 133.97 crores and total comprehensive income of Rs. 136.45 crores, for the period from 21 January 2026 to 31 March 2026. These financial results of JBCPL has been audited by other auditor who had expressed an unmodified opinion. Our opinion is not modified in respect of this matter. Ahmedabad 23 October 2026 For B S R & Co. LLP Chartered Accountants Firm's Registration No.: 101248W\/W-100022 Sadashiv Shetty Partner Membership No.: 048648 UDIN:26048648EXELKZ5012 Page 3 of 3 TORRENT\\\" PHARMA TORRENT PHARMACEUTICALS LIMITED Registered Office: \\\"Avirat'', Thaltej Shilaj Road, Ahmedabad - 380059, Gujarat, India, Ph.:+ 91 79 26599000 Fax:+ 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com Statement of Standalone Financial Results for the Quarter and Half Year ended September 30, 2026 Quarter ended Half Year ended 30-Sep-2026 30-Jun-2026 30-Sep-2025 30-Sep-2026 30-Sep-2025 Particulars Audited Unaudited Audited Audited Audited 1 Revenue from operations (a) Revenue from contracts with customers 4063 4073 2707 8136 5274 (b) Other operating income 82 85 55 167 104 Total revenue from operations 4145 4158 2762 8303 5378 2 Other income (Refer Note 8) (11) (21) (27) (32) (32) 3 Total income (1 + 2) 4134 4137 2735 8271 5346 4 Expenses (a) Cost of materials consumed 584 609 382 1193 776 (b) Purchases of stock-in-trade 369 277 186 646 359 (c) Changes in inventories of finished goods, work-in-progress 5 52 53 57 70 and stock-in-trade (d) Employee benefits expense 669 677 460 1346 913 (e) Finance costs 287 293 37 580 82 (f) Depreciation and amortisation expense 587 575 189 1162 376 (g) Other expenses 947 970 609 1917 1209 Total expenses 3448 3453 1916 6901 3785 5 Profit before exceptional items and tax (3 - 4) 686 684 819 1370 1561 6 Exceptional items (Refer Note 6) 10 21 13 31 13 7 Profit before tax (5 - 6) 676 663 806 1339 1548 8 Tax expense (a) Current tax 260 266 220 526 418 (b) Deferred tax (82) (95) (11) (177) (18) Total tax expense 178 171 209 349 400 9 Net profit for the period (7 \u2022 8) 498 492 597 990 1148 10 Other comprehensive income (A) (i) Items that will not be reclassified subsequently to (12) (17) (2) (29) (11) profit or loss (ii) Income tax relating to items that will not be 3 4 1 7 3 reclassified subsequently to profit or loss (B) (i) Items that will be reclassified subsequently to profit 18 107 (72) 125 (99) or loss (ii) Income tax relating to items that will be reclassified (4) {27) 18 {31) 25 subsequently to profit or loss Total other comprehensive income 5 67 (55) 72 (82) 11 Total comprehensive income (9 + 10) 503 559 542 1062 1066 12 Paid-up equity share capital (Face value of Rs. 5 each) 190.18 169.23 169.23 190.18 169.23 13 Other equity excluding revaluation reserves 14 Earnings per share (Face value of Rs. 5 each) (not annualised): Basic (in Rs.) 13.09 12.94 17.64 26.03 33.92 Diluted (in Rs.) 13.09 12.94 17.64 26.03 33.92 See accompanying notes to the standalone financial results ( Rs. in crores) Year ended 31-Mar-2026 Audited, Restated (Refer note 5) 11199 223 11422 (70) 11352 1748 832 (47) 1990 342 1057 2620 8542 2810 89 2721 767 (80) 687 2034 (3) 1 (191) 48 (145) 1889 169.23 17407 58.70 58.70 TORRENT\\\" PHARMA Notes: 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on October 23, 2026. The statutory auditors have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results. 2 The Company operates in a single segment i.e. Generic Formulation Business. 3 Standalone Balance Sheet Particulars A ASSETS 1 Non-current assets Property, plant and equipment Capital work-in-progress Investment properties Right-of-use assets Goodwill Other intangible assets Intangible assets under development Financial assets Investments Loans Other financial assets Other tax assets (net) Other non-current assets Total non-current assets 2 Current assets Inventories Financial assets Investments Trade receivables Cash and cash equivalents Bank balances other than cash and cash equivalents Loans Other financial assets Other current assets Total current assets 3 Non-current assets held for sale TOTAL ASSETS (1+2+3) (Rs. in crores) Audited As at 30-Sep-2026 As at 31-Mar-2026 Restated (Refer note S) 4123 3961 400 445 13 13 553 562 3917 3917 23234 24165 22 36 887 855 2 3 20 33 909 891 58 86 28 31 33257 34107 2221 2170 2073 866 3606 3350 82 97 22 48 5 5 220 531 6008 4897 574 538 8803 7605 1 1 42061 41713 TORRENT'\\\" PHARMA (Rs. in crores) Audited Particulars As .at As at 30-Sep-2026 31-Mar-2026 Restated (Refer note 5) B EQUITY AND LIABILITIES 1 Equity Equity share capital 190 169 Other equity 18066 17407 Total equity 18256 17576 2 Non-current liabilities Financial liabilities Borrowings 11428 11462 Lease liabilities 92 94 Other financial liabilities 29 86 11549 11642 Provisions 700 579 Deferred tax liabilities (net) 5524 5677 Other non-current liabilities 1 4 Total non-current liabilities 17774 17902 3 Current liabilities Financial liabilities Borrowings 1707 2703 Lease liabilities 22 21 Trade payables Total outstanding dues of micro enterprises and small enterprises 130 163 Total outstanding dues of creditors other than micro enterprises and 1131 1011 small enterprises Other financial liabilities 2147 1890 5137 5788 Other current liabilities 95 97 Provisions 298 280 Current tax liabilities (net) 501 70 Total current liabilities 6031 6235 TOTAL EQUITY AND LIABILITIES (1+2+3j 42061 41713 TORRENT'\\\" PHARMA 4 Standalone Statement of Cash Flows {Rs. in crores) Audited Particulars Half Vear ended Half Vear ended 30-Sep-2026 30-Sep-2025 A CASH FLOWS FROM OPERATING ACTIVITIES PROFIT BEFORE TAX 1339 1548 Adjustments for : Depreciation and amortisation expense 1162 376 Allowance for expected credit loss (net)* 6 0 Unrealised foreign exchange loss (net) 29 40 Loss on disposal of property, plant & equipment and other intangible assets 4 1 (including non-current assets held for sale) (net) Gain on sale of current investments (net) (53) (9) Finance costs 580 82 Rent income (2) - Interest income (9) (2) 3056 2036 Movement in working capital : Trade receivables (346) (428) Loans and other assets (10) (126) Inventories (51) 68 Trade payables 87 (7) Liabilities and provisions 63 (91) CASH GENERATED FROM OP\"},{\"summary\":\"a press release dated July 30, 2026, titled \\\"A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an Annexure B.\\\".\",\"category\":\"Press Release\",\"date\":\"30-Jul-2026 16:52:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_30072026165229_SE.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Unaudited Financial Results for quarter ended 30-Jun-26.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"30-Jul-2026 16:50:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_30072026164928_SE.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Acquisition - Disclosure pursuant to.\",\"category\":\"Acquisition\",\"date\":\"28-Sep-2026 12:03:00\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_28092026120242_SE_intimation_reg_30.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"Change in Director(s) of the company.\",\"category\":\"Change in Director(s)\",\"date\":\"01-Aug-2026 21:26:39\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_01082026212618_SE_Intimation_Ameera_Shah.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"a press release dated October 23, 2026, titled \\\"A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an Annexure B.\\\".\",\"category\":\"Press Release\",\"date\":\"23-Oct-2026 16:50:10\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_23102026165000_outcome.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"23-Oct-2026 16:45:57\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_23102026164512_Results.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated July 30, 2026, titled \\\"A Press Release on Financial Results which is being submitted to the media is also enclosedherewith as an Annexure B.\\\".\",\"category\":\"Press Release\",\"date\":\"30-Jul-2026 16:52:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_30072026165229_SE.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Unaudited Financial Results for quarter ended 30-Jun-26.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"30-Jul-2026 16:50:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/TORNTPHARM_30072026164928_SE.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3}],\"insider_activity\":[{\"person\":\"Jinesh Shah, Designated Person (in capacity of trustee of Jinesh Trust)\",\"category\":\"Other\",\"type\":\"Buy\",\"quantity\":\"930144\",\"post_holding\":\"930144\",\"date\":\"27-Nov-2024\",\"mode\":\"Gift\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":60.78,\"public_pct\":39.22,\"fii_pct\":17.22,\"dii_pct\":13.46,\"mf_pct\":8.82,\"institutional_pct\":30.68,\"noninst_pct\":8.54,\"mf_scheme_count\":46,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC MUTUAL FUND\",\"shares\":4341378,\"pct\":1.14},{\"name\":\"AXIS MUTUAL FUND TRUSTEE LIMITED A\/C AXIS MUTUAL FUND\",\"shares\":4243679,\"pct\":1.12},{\"name\":\"KOTAK DEBT HYBRID\",\"shares\":3996472,\"pct\":1.05}],\"period\":\"30-SEP-2026\",\"submission_date\":\"15-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739383_15102026075118_WEB.xml\",\"previous_period\":\"20-JUL-2026\",\"previous_promoter_pct\":60.78,\"previous_fii_pct\":17.97,\"previous_dii_pct\":12.87,\"previous_mf_pct\":8.27,\"previous_institutional_pct\":30.84,\"previous_mf_scheme_count\":44,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Torrent Pharmaceuticals L share price fell 1.97% to \u20b94,524.40 today. See why TORNTPHARM is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":8171,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Torrent Pharmaceuticals L Share Price Today: Why TORNTPHARM Is Falling 1.97% | 23 October 2026","_witty_meta_description":"Torrent Pharmaceuticals L share price fell 1.97% to \u20b94,524.40 today. See why TORNTPHARM is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Torrent Pharmaceuticals L share price today","_witty_reason_label":"Sector weakness and profit-taking following recent earnings announcements","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[149],"class_list":["post-8172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-torntpharm"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=8172"}],"version-history":[{"count":2,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8172\/revisions"}],"predecessor-version":[{"id":8376,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8172\/revisions\/8376"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/8171"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=8172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=8172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=8172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}